Spyre Therapeutics (SYRE) Return on Invested Capital (2022 - 2025)
Historic Return on Invested Capital for Spyre Therapeutics (SYRE) over the last 4 years, with Q3 2025 value amounting to 0.44%.
- Spyre Therapeutics' Return on Invested Capital rose 900.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year increase of 900.0%. This contributed to the annual value of 0.57% for FY2024, which is 14800.0% up from last year.
- As of Q3 2025, Spyre Therapeutics' Return on Invested Capital stood at 0.44%, which was up 900.0% from 0.41% recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Return on Invested Capital registered a high of 46.24% during Q2 2023, and its lowest value of 1.88% during Q1 2023.
- In the last 4 years, Spyre Therapeutics' Return on Invested Capital had a median value of 0.53% in 2024 and averaged 3.06%.
- Its Return on Invested Capital has fluctuated over the past 5 years, first surged by 474400bps in 2023, then tumbled by -468200bps in 2024.
- Over the past 4 years, Spyre Therapeutics' Return on Invested Capital (Quarter) stood at 1.44% in 2022, then soared by 743bps to 9.23% in 2023, then tumbled by -105bps to 0.47% in 2024, then increased by 7bps to 0.44% in 2025.
- Its last three reported values are 0.44% in Q3 2025, 0.41% for Q2 2025, and 0.4% during Q1 2025.